Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody...
Enregistré dans:
Auteurs principaux: | Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer |
---|---|
Format: | article |
Langue: | ZH |
Publié: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/73efbbca7aad481c9495e49e699bda8c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Expert consensus on diagnosis, treatment and fertility management of young breast cancer patients
par: Committee of Diagnosis, Treatment, and Fertility Management of Chinese Young Breast Cancer Patients
Publié: (2021) -
Chinese Expert Consensus on Iodine125 Seed Implantation for Recurrent Cervical Cancer in 2021
par: Ping Jiang, et autres
Publié: (2021) -
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
par: Nagasaka M, et autres
Publié: (2019) -
Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types
par: Zhe Gong, et autres
Publié: (2021) -
Targeting Tumor-Associated Macrophages in Cancer Immunotherapy
par: Amy J. Petty, et autres
Publié: (2021)